Results 181 to 190 of about 512,511 (217)

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

User eXperience Perception Insights Dataset (UXPID): Synthetic User Feedback from Public Industrial Forums. [PDF]

Sci Data
Kulyabin M, Joosten J, Ulan Uulu C, Martins Pacheco NM, Ries F, Petridis F, Bosch J, Olsson HH.   +7 more
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Protocol for the REVELIO test-track pilot study: A randomised, controlled, single-centre trial in healthy recreational cannabis users investigating real-time in-vehicle detection of cannabis-impaired driving. [PDF]

PLoS One
Deuber R, Bechny M, Heck C, Brügger J, Pfäffli M, Jovanova M, Fleisch E, Wortmann F, Weinmann W.   +8 more
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Transforming Brain Organoids Into Functional Platforms: Convergence of Engineering, Imaging, AI, and Ethics. [PDF]

Adv Sci (Weinh)
Pantula A, Joshi K, Samant S, Babakhanova G, Kathuria A.   +4 more
europepmc   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

A dataset of neural network architectures generated via large language models. [PDF]

Sci Data
Daoudi N, Cabot J.
europepmc   +1 more source

Determinants of procedural sedation requirements during endovascular treatment for acute anterior circulation ischaemic stroke: a post-hoc analysis of the INDIVIDUATE trial. [PDF]

Eur Stroke J
Chen M, Batra D, Bieber N, Sauer LD, Potreck A, Möhlenbruch M, Ringleb P, Schönenberger S.   +7 more
europepmc   +1 more source

Shotgun metagenomic profiling of the fecal microbiome in Lamp2 knockout mice reveals limited genotype-associated differences under standard housing. [PDF]

PLoS One
Emfietzoglou M, Bantounou MA, Osmani S, Narimatsu T, Baroutis KG, Varsamidaki A, Skondra D, Papaconstantinou D, Theodossiadis P, Chatziralli I, Miller JW, Vavvas DG.   +11 more
europepmc   +1 more source